A randomized, open-label, comparative, multi-center trial to evaluate the effects on hemostasis, lipids, carbohydrate metabolism, and on adrenal and thyroid function of a monophasic COC[combined oral contraceptive] containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [estradiol] compared to a monophasic COC containing 150 microg LNG[levonorgestrel] and 30 microg EE [ethinyl estradiol].
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Estradiol/nomegestrol (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Organon
- 01 Dec 2011 Results published in the European Journal of Contraception and Reproductive Health Care.
- 09 Oct 2009 Actual patient number (121) added as reported by ClinicalTrials.gov.
- 30 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.